Donaldson Capital Management LLC Has $403,000 Holdings in Merck & Company, Inc. (MRK)
Donaldson Capital Management LLC cut its stake in Merck & Company, Inc. (NYSE:MRK) by 9.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,291 shares of the company’s stock after selling 639 shares during the quarter. Donaldson Capital Management LLC’s holdings in Merck & were worth $403,000 at the end of the most recent reporting period.
Other large investors also recently made changes to their positions in the company. Conning Inc. increased its position in shares of Merck & by 1.4% during the second quarter. Conning Inc. now owns 595,075 shares of the company’s stock worth $38,138,000 after purchasing an additional 7,948 shares in the last quarter. Trillium Asset Management LLC grew its holdings in Merck & by 1.5% in the 2nd quarter. Trillium Asset Management LLC now owns 434,402 shares of the company’s stock valued at $27,840,000 after buying an additional 6,376 shares in the last quarter. Rational Advisors LLC grew its holdings in Merck & by 51.9% in the 2nd quarter. Rational Advisors LLC now owns 34,392 shares of the company’s stock valued at $2,205,000 after buying an additional 11,756 shares in the last quarter. Pinnacle Financial Partners Inc. grew its holdings in Merck & by 29.8% in the 2nd quarter. Pinnacle Financial Partners Inc. now owns 35,277 shares of the company’s stock valued at $2,261,000 after buying an additional 8,101 shares in the last quarter. Finally, Alpine Woods Capital Investors LLC grew its holdings in Merck & by 40.3% in the 2nd quarter. Alpine Woods Capital Investors LLC now owns 10,100 shares of the company’s stock valued at $647,000 after buying an additional 2,900 shares in the last quarter. 72.86% of the stock is owned by institutional investors.
Several analysts have issued reports on the company. Zacks Investment Research cut Merck & from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. BMO Capital Markets reissued a “buy” rating and set a $72.00 target price on shares of Merck & in a research note on Friday, September 8th. Citigroup Inc. set a $65.00 target price on Merck & and gave the stock a “hold” rating in a research note on Wednesday, July 5th. UBS AG increased their target price on Merck & from $70.00 to $72.00 and gave the stock a “buy” rating in a research note on Monday, July 31st. Finally, Piper Jaffray Companies set a $70.00 target price on Merck & and gave the stock a “buy” rating in a research note on Saturday, July 29th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $67.07.
Merck & (NYSE:MRK) last released its quarterly earnings data on Friday, October 27th. The company reported $1.11 earnings per share for the quarter, beating analysts’ consensus estimates of $1.03 by $0.08. Merck & had a net margin of 11.60% and a return on equity of 26.82%. The firm had revenue of $10.33 billion for the quarter, compared to analyst estimates of $10.54 billion. During the same period last year, the firm earned $1.07 earnings per share. The business’s quarterly revenue was down 2.0% compared to the same quarter last year.
COPYRIGHT VIOLATION NOTICE: “Donaldson Capital Management LLC Has $403,000 Holdings in Merck & Company, Inc. (MRK)” was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of international trademark and copyright legislation. The original version of this news story can be read at https://theolympiareport.com/2017/11/02/donaldson-capital-management-llc-has-403000-holdings-in-merck-company-inc-mrk.html.
About Merck &
Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.
Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.